Table 1 Patient characteristics
From: High-dose thiotepa-related neurotoxicity and the role of tramadol in children
| Patients (N = 251) | |
|---|---|
| Gender | |
| Boys | 145 (58%) |
| Girls | 106 (43%) |
| Age (years; median [IQR]) | 8 [5–15] |
| Race | |
| Caucasian | 186 (74%) |
| African | 40 (16%) |
| Others | 25 (10%) |
| Brain tumour | 116 (46%) |
| Medulloblastoma | 71 (28%) |
| PNETa | 26 (10%) |
| Pinealoblastoma | 13 (5%) |
| ATRTb | 5 (2%) |
| Malignant GCTc | 1 (0.4%) |
| Other tumour site | 135 (54%) |
| Osteosarcoma | 50 (20%) |
| Neuroblastoma | 26 (10%) |
| Ewing tumor | 23 (9%) |
| Rhabdomyosarcoma | 20 (8%) |
| Other sarcoma | 4 (2%) |
| Nephroblastoma | 4 (2%) |
| Burkitt lymphoma | 4 (2%) |
| Hepatoblastoma | 2 (1%) |
| Desmoplastic tumour | 2 (1%) |
| Neurological disorder at baselined | 20 (8%) |
| History of seizure | 13 (5%) |
| Thiotepa dose | |
| 600 mg/m2 | 129 (51%) |
| 720 mg/m2 | 76 (30%) |
| 900 mg/m2 | 46 (18%) |
| Concomitant drugse | |
| Alizapride | 94 (43%) |
| Antibiotic | 49 (22%) |
| Antidepressant | 7 (3%) |
| Antipsychotic | 40 (18%) |
| Aprepitant | 7 (3%) |
| Benzodiazepine | 43 (20%) |
| Histamine H2-receptor antagonist | 5 (2%) |
| Proton Pump Inhibitor | 7 (3%) |
| Analgesics | 92 (42%) |
| Simple analgesics | 76 (35%) |
| i.e. acetaminophen, nefopam | |
| Weak opioids | 53 (24%) |
| i.e. tramadol, codeine, dextropropoxyphen | |
| Strong opioids | 9 (4%) |
| i.e. morphine, pethidine | |
